palonosetron, dexamethasone, and 0.9% NaCl — Competitive Intelligence Brief

palonosetron, dexamethasone, and 0.9% NaCl (palonosetron, dexamethasone, and 0.9% NaCl) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antiemetic combination. Area: Oncology.

phase 3 antiemetic combination 5-HT3 receptors, glucocorticoid receptors Oncology Small molecule

Target snapshot

palonosetron, dexamethasone, and 0.9% NaCl (palonosetron, dexamethasone, and 0.9% NaCl) — Sixth Affiliated Hospital, Sun Yat-sen University. Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
palonosetron, dexamethasone, and 0.9% NaCl TARGET	palonosetron, dexamethasone, and 0.9% NaCl	Sixth Affiliated Hospital, Sun Yat-sen University	phase 3	antiemetic combination	5-HT3 receptors, glucocorticoid receptors
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor
Dexamethasone+NK-1 RA+5-HT3 RA	Dexamethasone+NK-1 RA+5-HT3 RA	Fifth Affiliated Hospital, Sun Yat-Sen University	phase 3	Antiemetic combination therapy	Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor
Ondansetron, dexamethasone, aprepitant	Ondansetron, dexamethasone, aprepitant	University of Oklahoma	phase 3	Antiemetic combination (5-HT3 antagonist, NK1 antagonist, corticosteroid)	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Aprepitant+palonosetron+dexamethasone	Aprepitant+palonosetron+dexamethasone	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	phase 3	Antiemetic combination (NK1 antagonist + 5-HT3 antagonist + corticosteroid)	NK1 receptor, 5-HT3 receptor, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antiemetic combination class)

1. Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class